Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00157716 · ClinicalTrials.gov registry record · Phase 2
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
A Phase 2 study, sponsored by Medicure.
- Completed
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
NCT00157716 is a Phase 2 study that has completed, run by Medicure. The registered enrollment target is 900 participants.
The verdict
NCT00157716, a Phase 2 study, has completed, sponsored by Medicure.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery
Interventions
- DRUG (MC-1) Pyridoxal-5'-phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00157716
The ClinicalTrials.gov registry entry for NCT00157716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicure, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which (MC-1) Pyridoxal-5'-phosphate is the first listed.
NCT00157716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00157716 about?
NCT00157716 is a clinical study titled "MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)". The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery
What is the current status of trial NCT00157716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2004-04. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00157716?
The interventions under investigation include: (MC-1) Pyridoxal-5'-phosphate (DRUG).
Who is sponsoring clinical trial NCT00157716?
This trial is sponsored by Medicure, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.